clinical-stage biopharma atai Life Sciences (NASDAQ: ATAI), focused on transforming mental health treatment, announced a strategic investment in Beckley Psytech, cementing its position as the bio-pharma leader with the broadest portfolio of clinical-stage psychedelic drug candidates.

On February 21, 2024, Innovent Biologics and ImmVirX unveiled a partnership for clinical research on a combo therapy using sintilimab and the cancer-fighting virus IVX037.

Hutchmed and Inmagene have exercised licensing options for two drug candidates, IMG-007 and IMG-004, as per their strategic collaboration agreement.

On January 24, 2024, Novo Nordisk partnered with EraCal Therapeutics to co-develop an appetite and weight control drug.

On January 30, 2024, Regeneron revealed plans to acquire 2seventy bio's immuno-cell therapy pipeline and related manufacturing capabilities under a new agreement.

Merck Sharp & Dohme (MSD) and Harpoon Therapeutics announced a deal for MSD to purchase Harpoon at $23/share, totaling around $680 million in equity.

Bristol Myers Squibb (BMS) and RayzeBio announced a definitive merger, with BMS acquiring RayzeBio for $62.50/share in a deal valued at about $4.1 billion, netting $3.6 billion after accounting for RayzeBio's $500 million cash.

Bristol Myers Squibb (BMS) has agreed to acquire Karuna Therapeutics for around $14 billion, obtaining their novel schizophrenia treatment, KarXT.

Argo Biopharma unveiled exclusive RNAi therapy licensing deals with Novartis Pharma.

Calypso Biotech to be acquired by Novartis under a deal with a $250M upfront and potential $175M in milestones, with their lead antibody, CALY-002, targeting IL-15.

Novartis Pharma will purchase SanReno Therapeutics, enhancing its kidney treatment range. Following the acquisition, SanReno will join Novartis China, advancing clinical trials of two important IgA nephropathy treatments, atrasentan and BION-1301.

On Jan 17, 2024, Windtree Therapeutics announced a licensing deal with Lee's Pharm for its heart failure drug istaroxime in Greater China.